GlassScriptPhysician profile
Edward T Kim
NPI 1609011204
$79,433.13
in general payments reported to CMS, 2019-2025
28 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $9,457 · 2021: $5,719 · 2022: $8,870 · 2023: $12K · 2024: $2,933 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,945 · Travel and Lodging: $3,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,281.25 |
| Food and Beverage | $11,907.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,945.00 |
| Travel and Lodging | $3,366.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24,293.78 | 2019-2025 | Aveir, Tacticath Ablation Catheter, Sensor Enabled, Jot Dx |
| Medtronic, INC. | $21,388.82 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Biosense Webster, INC. | $11,146.25 | 2019-2025 | Carto 3, Thermocool Sf, Nuvision Ice Catheter |
| Medical Device Business Services, INC. | $9,000.00 | 2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $8,978.17 | 2020-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $839.40 | 2019-2024 | Rhythmia Mapping System, Lux-Dx Insertable Cardiac Monitor |
| Impulse Dynamics (USA) INC. | $793.76 | 2022-2025 | Optimizer, Optimizer |
| Biotronik INC. | $636.46 | 2019-2025 | Biomonitor |
| Edwards Lifesciences Corporation | $459.04 | 2024-2025 | Sapien 3 Ultra Resilia |
| Mirati Therapeutics, INC. | $431.25 | 2023 | Krazati |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $297.06 | 2019-2024 | Lifevest |
| Cardiva Medical, INC. | $296.52 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Ensoetm |
| Novartis Pharmaceuticals Corporation | $186.14 | 2021-2025 | |
| Medtronic Vascular, INC. | $110.00 | 2019-2020 | |
| Philips North America LLC | $70.82 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $65.13 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $62.09 | 2024 | Repatha |
| Terumo Medical Corporation | $54.95 | 2019-2022 | |
| Cvrx, INC. | $53.22 | 2025 | Barostim Neo System |
| Sumitomo Pharma America, INC. | $41.80 | 2024 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $38.61 | 2025 | Uptravi, Opsumit |
| Irhythm Technologies, INC. | $36.37 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $32.10 | 2024 | |
| Acist Medical Systems, INC. | $31.94 | 2019-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $27.83 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $23.77 | 2019 | |
| Altathera Pharmaceuticals LLC | $20.52 | 2025 | Sotalol Hydrochloride |
| Astrazeneca Pharmaceuticals LP | $17.33 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.